Kymera Therapeutics

Kymera Therapeutics, Inc. operates as a biotechnology company, which engages in curing untreatable diseases. It focuses on discovering and developing novel small molecule therapeutics. The firm's proprietary integrated degradation platform consists of informatics-driven target identification, novel E3 ligases and ligands, proprietary predictive modeling, and novel degradation tools. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Kymera Therapeutics reports successful 2022, eyes growth through strategic partnerships

Kymera Therapeutics had a successful year, with promising data in multiple programs and a focus on targeted protein degradation.
The company's financial position is strong, with key goals set for 2023, including collaborations and advancing pipeline programs.
Challenges lie in program prioritization, mechanism of action clarity, and optimizing dosing strategies, while opportunities exist in partnerships and therapeutic innovation.
Overall, Kymera's innovative approach and strategic outlook position it well for growth and continued success in 2023.

Kymera Therapeutics reports solid Q1 performance and eyes clinical milestones

Kymera Therapeutics is progressing well in its pipeline development, focusing on innovative programs with broad enrollment criteria.
Financially, the company is stable with a strong cash position and a clear runway into the future.
While facing challenges in capital allocation and program development, Kymera is actively seeking opportunities for growth and collaboration.

Kymera Therapeutics reports robust earnings, advances in clinical trials

Kymera Therapeutics showcased strong financial performance, progress in clinical trials, and a patient-centric approach to drug development.
While facing challenges in clarity on certain trial aspects and partnership limitations, the company is well-positioned for growth and innovation.
Opportunities lie in expanding clinical studies, developing new INDs, and exploring additional indications for their drug portfolio.

Kymera Therapeutics achieves clinical milestones and financial stability for growth

Kymera Therapeutics has made significant progress in clinical development and financial stability, positioning the company for future growth and success.
The company's focus on genetically validated targets, degrader mechanisms, and combination therapies underscores a strategic and innovative approach to drug development.
While facing challenges in dose optimization and safety standards, Kymera has opportunities to leverage its strengths in solid tumors and immunology for therapeutic advancements.
Overall, Kymera's performance, strengths, and opportunities outweigh the challenges, indicating a promising outlook for the company's future in the biopharmaceutical industry.

Kymera Therapeutics reports robust earnings, advances oral immunology pipeline

Kymera Therapeutics is in a strong financial position with a clear runway for growth, focusing on advancing their oral immunology pipeline and strategic partnerships. They face challenges in prioritizing indications but have opportunities for collaborations and innovative therapeutic development.
The company's progress in clinical programs, including dose escalation trials and milestone achievements, reflects their commitment to advancing novel therapies and addressing unmet medical needs in inflammatory diseases, oncology, and immunology.

Kymera Therapeutics reports solid Q1 performance and eyes program expansion

Kymera Therapeutics had a strong start in 2024 with promising program updates and financial stability.
The company's focus on innovative degrader medicines and potential indication expansion positions it for future growth.
Challenges in data disclosure timing and partnership decisions require strategic navigation for sustained success.
Overall, Kymera's performance, strengths, and opportunities indicate a positive trajectory with key milestones ahead.

Kymera Therapeutics reports strong Q2 earnings and eyes CNS expansion

Kymera Therapeutics showcased strong financial performance, progress in clinical trials, and a focus on innovative drug development approaches.
While facing challenges in market competition and financial management, the company is well-positioned to capitalize on growth opportunities.
Overall, Kymera's emphasis on developing effective oral immunology drugs and exploring CNS indications sets a positive trajectory for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.

WATERTOWN, Mass., June 28, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that it has commenced an underwritten public offering of 4,000,000 shares of its common stock. All of the shares are being offered by Kymera. In addition, Kymera intends to grant the underwriters a 30-day option to purchase up to an additional 600,000 shares of its common stock.

Kymera Therapeutics Announces Proposed Public Offering of Common Stock

The stock price of Kymera Therapeutics Inc (NASDAQ: KYMR) increased over 8% pre-market. This is why it happened.

KYMR Stock Price Increases Over 8% Pre-Market: Why It Happened

Kymera Therapeutics Inc (NASDAQ: KYMR) has announced interim results from the Single Ascending Dose (SAD) portion of the Phase 1 trial of KT-474 in healthy volunteers. KT-474 has exceeded the Phase 1 target degradation of 85% to date, with robust IRAK4 degradation after a single oral dose lasting for at least six days at all dose levels.

Kymera's KT-474 Achieved Sustained IRAK4 Reduction After Single Dose In Healthy Volunteers

KT-474 has achieved and exceeded Phase 1 target degradation of 85% within the SAD portion of the Phase 1 trial dosed to date, with 90% median degradation at the 300 mg dose

Kymera Therapeutics Announces Positive Interim Results from Single Ascending Dose Phase 1 Trial of KT-474 Demonstrating Degrader Proof-of-Mechanism

WATERTOWN, Mass., June 21, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of Elaine Caughey, MBA, as Chief Business Officer. Ms. Caughey joins Kymera with over 20 years of experience in the biotechnology industry, including leadership roles in corporate development, business and commercial operations, new product strategy, and investing.

Kymera Therapeutics Appoints Elaine Caughey, MBA, as Chief Business Officer

Kymera Therapeutics Inc (NASDAQ: KYMR) has announced new preclinical data on its IRAKIMiD degrader KT-413's potential as both a monotherapy and in combination with other anticancer agents. The data were featured at the Annual International Conference on Malignant Lymphoma (ICML) virtual meeting.

Kymera Therapeutics' KT-413 Shows Encouraging Preclinical Anti-Cancer Activity

WATERTOWN, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9 at 4:40 p.m. ET.

Kymera Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference

Novel E3 ligase identified by Kymera's Whole-Body Atlas is expressed in selected tissues while broadly expressed in cancer cells

Kymera Therapeutics Presents New Data Demonstrating Proof-of-Degradation Using Novel Tissue-Restricted E3 Ligase

New in vivo data demonstrate the broad anti-inflammatory activity of KT-474 and its superiority compared to a clinically active small molecule IRAK4 kinase inhibitor in preclinical immune-inflammatory models

Kymera Therapeutics Presents Late-Breaking Preclinical Data on IRAK4 Degrader KT-474 at IMMUNOLOGY2021™ Annual Meeting

Phase 1 trial of first-in-class oral IRAK4 degrader KT-474 initiated in February; on track to present human proof-of-biology data in 4Q 2021

Kymera Therapeutics Announces First Quarter 2021 Financial Results and Provides a Business Update

WATERTON, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will present at the upcoming investor conferences:

Kymera Therapeutics to Present at Upcoming May Investor Conferences

Data demonstrate KT-474's superiority compared to a clinically active small molecule IRAK4 kinase inhibitor across a wide variety of immune-inflammatory preclinical models Data demonstrate KT-474's superiority compared to a clinically active small molecule IRAK4 kinase inhibitor across a wide variety of immune-inflammatory preclinical models

Kymera Therapeutics to Present New In Vivo Data Demonstrating the Broad Anti-Inflammatory Activity of its IRAK4 Degrader KT-474 at IMMUNOLOGY2021™ Annual Meeting

WATERTOWN, Mass., April 19, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Boston Business Journal (BBJ) has named Kymera Therapeutics to its 2021 Best Places to Work, an exclusive ranking of the Massachusetts companies that have built outstanding work environments for their people.

Kymera Therapeutics Honored by Boston Business Journal as a 2021 Best Places to Work Company

The stock price of Kymera Therapeutics Inc (NASDAQ: KYMR) increased by 16.76%. This is why it happened.

KYMR Stock: 16.76% Increase Explanation

KT-413-mediated degradation of IRAK4 and IMiD substrates has synergistic effect on MYD88-NFkB and IRF4-Type 1 Interferon pathways resulting in superior antitumor activity in MYD88-mutant DLBCL models compared to IMiDs or selective IRAK4 targeting alone

Kymera Therapeutics Presents Late-Breaking Preclinical Data Highlighting Superiority of Dual-Targeting Activity of IRAKIMiD Degrader KT-413 at AACR Annual Meeting 2021

WATERTOWN, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that a late-breaking abstract featuring new data in patients with hidradenitis suppurativa (HS) from its non-interventional study of patients with HS or atopic dermatitis (AD) has been selected for presentation at the Society for Investigative Dermatology (SID) 2021 Annual Meeting, being held virtually May 3-8, 2021. The non-interventional study is evaluating expression of IRAK4 and other mediators of inflammation in the skin and blood of patients with HS or AD and the ex vivo effect of the IRAK4 degrader KT-474.

Kymera Therapeutics to Present New Results from Non-Interventional Study in Patients with Hidradenitis Suppurativa at the Society for Investigative Dermatology (SID) 2021 Annual Meeting

WATERTOWN, Mass., March 16, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointment of Elena Ridloff, CFA, to its Board of Directors, where she will serve as Chair of the Audit Committee. Ms. Ridloff joins Kymera's Board with two decades of biopharmaceutical industry experience, including senior leadership positions at commercial-stage companies and as an institutional investor.

Kymera Therapeutics Appoints Elena Ridloff, CFA, to Board of Directors

KT-474 is the first IRAK4 degrader, and first heterobifunctional small molecule protein degrader outside of oncology, to enter clinical development

Kymera Therapeutics Announces First-in-Human Dose in Phase 1 Trial of KT-474, a First-in-Class IRAK4 Protein Degrader to Treat Immune-Inflammatory Diseases

WATERTOWN, Mass., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will participate in upcoming investor conferences:

Kymera Therapeutics to Present at Upcoming March Investor Conferences

WATERTOWN, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the appointments of Ashwin Gollerkeri, MD, as Senior Vice President, Head of Development, and Kevin Dushney, as Vice President, Information Technology, as well as the promotion of Karen Martin, JD, PhD to Vice President, Head of Legal.

Kymera Therapeutics Strengthens Leadership with Key Appointments and Promotions

Annexon, Inc

ASA Gold and Precious Metals Ltd

Blackrock Health Sciences Trust

BlackRock Health Sciences Trust II

BlackRock Science & Technology

BlackRock Science and Technology Trust II

Genmab - ADR

Masimo

Oak Street Health

Seagen

Sigilon Therapeutics

Taysha Gene Therapies

BMEZ delivered solid results throughout 2020, helped by the healthcare sector overall. This fund doesn't just invest in your typical healthcare companies though and tilts towards smaller and private investments.

BMEZ: Healthcare Exposure With A ~4% Yield And Growth Potential

Kymera is one of several biotechs pioneering targeted protein degradation science and technology - removing unwanted proteins by marking them for destruction by the proteasome. The company IPOd in August 2020, and shares have risen from $20, to $79.6 at the time of writing as enthusiasm for the sector rises.

Kymera Therapeutics Is A Protein Degrading Pioneer With A Triple-Figure Share Price In Waiting

WATERTOWN, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will present at the virtual 39th Annual J.P. Morgan Healthcare Conference at 2:00 p.m. ET on Thursday, January 14, 2021. Nello Mainolfi, PhD, Co-Founder, President and CEO of Kymera, will provide an overview of the Company's progress and anticipated milestones for 2021.

Kymera Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021

WATERTOWN, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel, small molecule protein degrader therapeutics, today announced the appointments of William Leong, PhD, as Vice President of Chemistry, Manufacturing and Controls (CMC) and Paul Cox as Vice President of Investor Relations and Communications.

Kymera Therapeutics Announces Key Leadership Appointments

WATERTOWN, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel, small molecule protein degrader therapeutics, today announced the company presented preclinical data that further support development of its highly selective and potent IRAKIMiD and STAT3 protein degraders scheduled to enter the clinic in 2021. Data were presented at the virtual 62nd American Society of Hematology (ASH) Annual Meeting, Dec. 5-8, 2020 in three separate poster presentations.

News for Kymera Therapeutics Stock (KYMR)